Compare Enveric Biosciences Inc (ENVB) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Otis Worldwide Corp — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Otis Worldwide Corp trades at $66.21 (market cap $25.17B). The key difference: Otis Worldwide Corp is far larger — about 3701.5× Enveric Biosciences Inc's market cap, and Otis Worldwide Corp pays a 2.66% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Otis Worldwide Corp for 65 Days on average.
| ENVB | OTIS | |
|---|---|---|
Market Cap | $6.80M | $25.17B |
Volume | 64,867 | 4,542,442 |
Sector | Health | Industrials |
52-Week High | $10.80 | $93.62 |
52-Week Low | $1.27 | $64.05 |
Typical Hold Time | 14 Days | 65 Days |
Enterprise Value | -$1.49M | $33.20B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Otis Worldwide trades at $65.74, down 1.07% with a bearish technical signal and recent earnings misses. The stock trades near its 52-week low with mixed analyst sentiment (46.7% buy, 46.7% hold) despite a consensus price target of $87.00. Revenue growth remains stable at $14.43B (2025) with 10.17% net margins, though service margins face pressure from labor costs. Recent CEO succession news and China project wins provide strategic context amid weak equipment demand.
The outlook balances stable service revenue against margin pressures and China exposure. Upside exists if service margins recover and modernization backlog converts, but near-term headwinds and technical weakness suggest cautious positioning. Key risks include prolonged China weakness and execution on cost controls.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
